BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28435533)

  • 1. Discovery of Antimalarial Azetidine-2-carbonitriles That Inhibit
    Maetani M; Kato N; Jabor VAP; Calil FA; Nonato MC; Scherer CA; Schreiber SL
    ACS Med Chem Lett; 2017 Apr; 8(4):438-442. PubMed ID: 28435533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicinal chemistry approaches for the discovery of
    Vyas VK; Shukla T; Sharma M
    Future Med Chem; 2023 Jul; 15(14):1295-1321. PubMed ID: 37551689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
    Singh A; Maqbool M; Mobashir M; Hoda N
    Eur J Med Chem; 2017 Jan; 125():640-651. PubMed ID: 27721149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances on patents of
    Gehlot P; Vyas VK
    Expert Opin Ther Pat; 2023; 33(9):579-596. PubMed ID: 37942637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model.
    Mandt REK; Lafuente-Monasterio MJ; Sakata-Kato T; Luth MR; Segura D; Pablos-Tanarro A; Viera S; Magan N; Ottilie S; Winzeler EA; Lukens AK; Gamo FJ; Wirth DF
    Sci Transl Med; 2019 Dec; 11(521):. PubMed ID: 31801884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of QSAR Method in the Design of Enhanced Antimalarial Derivatives of Azetidine-2-carbonitriles, their Molecular Docking, Drug-likeness, and SwissADME Properties.
    Ibrahim ZY; Uzairu A; Shallangwa GA; Abechi SE
    Iran J Pharm Res; 2021; 20(3):254-270. PubMed ID: 34903987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of 7-arylaminopyrazolo[1,5-a]pyrimidines as anti-Plasmodium falciparum, antimalarial, and Pf-dihydroorotate dehydrogenase inhibitors.
    Azeredo LFSP; Coutinho JP; Jabor VAP; Feliciano PR; Nonato MC; Kaiser CR; Menezes CMS; Hammes ASO; Caffarena ER; Hoelz LVB; de Souza NB; Pereira GAN; Cerávolo IP; Krettli AU; Boechat N
    Eur J Med Chem; 2017 Jan; 126():72-83. PubMed ID: 27744189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors.
    Vyas VK; Ghate M
    Mini Rev Med Chem; 2011 Oct; 11(12):1039-55. PubMed ID: 21861807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions.
    Deng X; Matthews D; Rathod PK; Phillips MA
    Acta Crystallogr F Struct Biol Commun; 2015 May; 71(Pt 5):553-9. PubMed ID: 25945708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening.
    Pavadai E; El Mazouni F; Wittlin S; de Kock C; Phillips MA; Chibale K
    J Chem Inf Model; 2016 Mar; 56(3):548-62. PubMed ID: 26915022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of Potent Inhibitors of P. falciparum Dihydroorotate Dehydrogenase for the Treatment of Malaria.
    Skerlj RT; Bastos CM; Booker ML; Kramer ML; Barker RH; Celatka CA; O'Shea TJ; Munoz B; Sidhu AB; Cortese JF; Wittlin S; Papastogiannidis P; Angulo-Barturen I; Jimenez-Diaz MB; Sybertz E
    ACS Med Chem Lett; 2011 Sep; 2(9):708-13. PubMed ID: 24900364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmodium falciparum dihydroorotate dehydrogenase: a drug target against malaria.
    Hoelz LV; Calil FA; Nonato MC; Pinheiro LC; Boechat N
    Future Med Chem; 2018 Aug; 10(15):1853-1874. PubMed ID: 30019917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.
    Kokkonda S; Deng X; White KL; Coteron JM; Marco M; de Las Heras L; White J; El Mazouni F; Tomchick DR; Manjalanagara K; Rudra KR; Chen G; Morizzi J; Ryan E; Kaminsky W; Leroy D; Martínez-Martínez MS; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Waterson D; Burrows JN; Matthews D; Charman SA; Phillips MA; Rathod PK
    J Med Chem; 2016 Jun; 59(11):5416-31. PubMed ID: 27127993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, Design, and Structure⁻Activity Relationship of the Pyrimidone Derivatives as Novel Selective Inhibitors of
    Xu L; Li W; Diao Y; Sun H; Li H; Zhu L; Zhou H; Zhao Z
    Molecules; 2018 May; 23(6):. PubMed ID: 29794978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoxazolopyrimidine-Based Inhibitors of
    Kokkonda S; El Mazouni F; White KL; White J; Shackleford DM; Lafuente-Monasterio MJ; Rowland P; Manjalanagara K; Joseph JT; Garcia-Pérez A; Fernandez J; Gamo FJ; Waterson D; Burrows JN; Palmer MJ; Charman SA; Rathod PK; Phillips MA
    ACS Omega; 2018 Aug; 3(8):9227-9240. PubMed ID: 30197997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of carbohybrid-based 2-aminopyrimidine analogues as a new class of rapid-acting antimalarial agents using image-based cytological profiling assay.
    Lee S; Lim D; Lee E; Lee N; Lee HG; Cechetto J; Liuzzi M; Freitas-Junior LH; Song JS; Bae MA; Oh S; Ayong L; Park SB
    J Med Chem; 2014 Sep; 57(17):7425-34. PubMed ID: 25137549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyazole scaffold-based Plasmodium falciparum dihydroorotate dehydrogenase inhibitors: Synthesis, biological evaluation and X-ray structural studies.
    Pippione AC; Sainas S; Goyal P; Fritzson I; Cassiano GC; Giraudo A; Giorgis M; Tavella TA; Bagnati R; Rolando B; Caing-Carlsson R; Costa FTM; Andrade CH; Al-Karadaghi S; Boschi D; Friemann R; Lolli ML
    Eur J Med Chem; 2019 Feb; 163():266-280. PubMed ID: 30529545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
    Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
    Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
    Phillips MA; White KL; Kokkonda S; Deng X; White J; El Mazouni F; Marsh K; Tomchick DR; Manjalanagara K; Rudra KR; Wirjanata G; Noviyanti R; Price RN; Marfurt J; Shackleford DM; Chiu FC; Campbell M; Jimenez-Diaz MB; Bazaga SF; Angulo-Barturen I; Martinez MS; Lafuente-Monasterio M; Kaminsky W; Silue K; Zeeman AM; Kocken C; Leroy D; Blasco B; Rossignol E; Rueckle T; Matthews D; Burrows JN; Waterson D; Palmer MJ; Rathod PK; Charman SA
    ACS Infect Dis; 2016 Dec; 2(12):945-957. PubMed ID: 27641613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of 4-Amino 2-Anilinoquinazolines against
    Gilson PR; Nguyen W; Poole WA; Teixeira JE; Thompson JK; Guo K; Stewart RJ; Ashton TD; White KL; Sanz LM; Gamo FJ; Charman SA; Wittlin S; Duffy J; Tonkin CJ; Tham WH; Crabb BS; Cooke BM; Huston CD; Cowman AF; Sleebs BE
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.